PainReform Ltd. Confirms Suture Compatibility in Human Clinical Trials for PRF-110 Page 1

Positive compatibility results confirm the safety and efficacy of PRF-110 in postoperative pain management

TEL AVIV, Israel, September 11, 2024 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReformation” or the “Company“), a pharmaceutical company focused on reformulating existing clinical-stage therapies, today announced positive suture compatibility findings in human clinical trials of its lead product, PRF-110. PRF-110 is designed to provide long-term, non-opiate pain relief following surgery.

The company conducted extensive in vitro studies to evaluate the impact of PRF-110 on both nonabsorbable and absorbable sutures. Since suture materials are often in close proximity to the PRF-110 oil solution following surgery, it was critical to evaluate whether PRF-110 would affect the mechanical properties of these sutures. The mechanical integrity, including breaking force and elongation, of PROLENE nonabsorbable sutures and Vicryl absorbable sutures were tested at baseline (time zero) and 14 days, with comparisons to a control group.